Axon Enterprise (NASDAQ:AXON) Reaches New 1-Year High – Should You Buy?

Shares of Axon Enterprise, Inc. (NASDAQ:AXON) hit a new 52-week high during mid-day trading on Monday . The company traded as high as $441.33 and last traded at $441.24, with a volume of 152275 shares. The stock had previously closed at $438.05.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. JMP Securities increased their price target on shares of Axon Enterprise from $375.00 to $430.00 and gave the company an “outperform” rating in a report on Thursday, September 12th. Northland Securities lifted their target price on Axon Enterprise from $330.00 to $365.00 and gave the stock an “outperform” rating in a research report on Thursday, August 8th. Barclays lifted their target price on Axon Enterprise from $381.00 to $387.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. Jefferies Financial Group began coverage on Axon Enterprise in a research report on Wednesday, July 17th. They set a “buy” rating and a $385.00 target price on the stock. Finally, Craig Hallum lifted their target price on Axon Enterprise from $370.00 to $376.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $365.38.

Axon Enterprise Stock Up 1.4 %

The business’s 50 day moving average price is $388.71 and its 200-day moving average price is $331.95. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.88 and a quick ratio of 2.52. The company has a market cap of $33.55 billion, a P/E ratio of 116.70, a PEG ratio of 11.74 and a beta of 0.94.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.18. Axon Enterprise had a net margin of 16.06% and a return on equity of 9.34%. The firm had revenue of $504.00 million during the quarter, compared to analysts’ expectations of $478.35 million. During the same quarter in the previous year, the company posted $0.80 EPS. Axon Enterprise’s revenue was up 34.5% on a year-over-year basis. On average, analysts anticipate that Axon Enterprise, Inc. will post 1.79 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Axon Enterprise news, Director Michael Garnreiter sold 1,000 shares of Axon Enterprise stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $437.98, for a total transaction of $437,980.00. Following the completion of the sale, the director now owns 26,259 shares of the company’s stock, valued at approximately $11,500,916.82. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, Director Michael Garnreiter sold 1,000 shares of the business’s stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $437.98, for a total value of $437,980.00. Following the completion of the transaction, the director now owns 26,259 shares of the company’s stock, valued at $11,500,916.82. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Patrick W. Smith sold 4,767 shares of the business’s stock in a transaction on Thursday, October 3rd. The shares were sold at an average price of $404.14, for a total transaction of $1,926,535.38. Following the completion of the transaction, the chief executive officer now directly owns 2,925,060 shares of the company’s stock, valued at $1,182,133,748.40. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 371,172 shares of company stock valued at $137,000,162. Company insiders own 6.10% of the company’s stock.

Hedge Funds Weigh In On Axon Enterprise

Institutional investors and hedge funds have recently made changes to their positions in the company. Blue Trust Inc. boosted its stake in Axon Enterprise by 987.5% in the 2nd quarter. Blue Trust Inc. now owns 87 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 79 shares during the period. Trivant Custom Portfolio Group LLC acquired a new position in Axon Enterprise in the 1st quarter worth $31,000. Quent Capital LLC boosted its stake in Axon Enterprise by 1,875.0% in the 3rd quarter. Quent Capital LLC now owns 79 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 75 shares during the period. First PREMIER Bank acquired a new position in Axon Enterprise in the 1st quarter worth $33,000. Finally, Asset Dedication LLC bought a new stake in Axon Enterprise during the 2nd quarter worth about $47,000. Institutional investors and hedge funds own 79.08% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.